| The Chennai based Bafna Pharmaceuticals, engaged in the business of manufacturing of pharmaceutical formulations of betalactum and non–betalactum, has received approval from Ghana Food and Drug Administration (FDA) for metformin tablets 500mg, a drug used by the diabetic patients. |
| This is the 8th formulation approval received from Ghana FDA for a product by Bafna Pharmaceuticals. Recently Bafna Pharma had received the Australian Therapeutic Goods Administration (TGA) approval on manufacturing of both prescription and non-prescription products in the Australian market. |
| Metformin is an oral anti-diabetic drug in the biguanide class. It is the first-line drug of choice for the treatment of type 2 diabetes, particularly in overweight and obese people and those with normal kidney function. Evidence is also mounting for its efficacy in gestational diabetes. It is also used in the treatment of polycystic ovary syndrome and has been investigated for other diseases where insulin resistance may be an important factor. |
No comments:
Post a Comment